2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/13/18XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer StudyPrinter Friendly Version
12/12/18XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin DiseasePrinter Friendly Version
12/03/18XBiotech Announces Successful Completion of GMP AuditPrinter Friendly Version
10/31/18XBiotech Highlights Third Quarter Developments for 2018Printer Friendly Version
10/26/18XBiotech Announces New Patents for Third Quarter 2018Printer Friendly Version
10/24/18XBiotech Announces Dismissal of Securities Class Action SuitPrinter Friendly Version
10/05/18XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic DermatitisPrinter Friendly Version
09/26/18XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin DiseasesPrinter Friendly Version
09/24/18XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis SuppurativaPrinter Friendly Version
09/20/18XBiotech Announces Addition of Top Dermatologist and Researcher Dr. Alice Gottlieb to its TeamPrinter Friendly Version
09/13/18XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic DermatitisPrinter Friendly Version
09/12/18XBiotech Announces Addition of World Leading Cardiologist Dr. Peter Libby to its Scientific Advisory BoardPrinter Friendly Version
08/27/18XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart AttacksPrinter Friendly Version
08/10/18XBiotech Highlights Quarterly DevelopmentsPrinter Friendly Version
07/10/18XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis SuppurativaPrinter Friendly Version
05/22/18XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic DermatitisPrinter Friendly Version
04/16/18XBiotech Announces Upcoming Phase 2 Clinical Studies in DermatologyPrinter Friendly Version
04/02/18XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced CancerPrinter Friendly Version
01/26/18XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaPrinter Friendly Version
01/25/18XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureusPrinter Friendly Version
01/19/18XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis SuppurativaPrinter Friendly Version